Clinical Trials on Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck in Colombia

Total 119 results

British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Johns Hopkins University
Castle Biosciences Incorporated

Recruiting

Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States
Rain Oncology Inc

Terminated

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

Korea, Republic of, United States, France, Australia, Israel, Spain, United Kingdom, Switzerland
Sensei Biotherapeutics, Inc.

Terminated

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
National Baromedical Services
Mayo Clinic; Dartmouth-Hitchcock Medical Center; CISSS de Chaudière-Appalaches; Memorial Hermann Hospital and other collaborators

Not yet recruiting

Hyperbaric Radiation Sensitization of Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
University of Missouri-Columbia

Recruiting

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer (ENID)

Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Cancer of the Head and Neck | Throat Carcinoma

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
GlaxoSmithKline

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Italy, Japan, Norway, Spain, Taiwan, Australia, United Kingdom, Belgium, Brazil, Germany, Greece, Romania, Sweden, Turkey, Canada, Korea, Republic of, China, France, Argentina, India, Poland, Israel, Portugal, Mexico, Czechia, Hunga...
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, United Kingdom, Canada
University of Maryland, Baltimore

Recruiting

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) (SAVAL)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell Carcinoma

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)

Neoplasms, Head and Neck

United States, Argentina, Australia, Spain, Taiwan, Germany, Israel, Poland, Canada, Japan, Portugal, Ireland, Netherlands, China, Brazil, France, Korea, Republic of, Italy, Romania, Russian Federation, United Kingdom, Norway, Switz... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Head and Neck Neoplasms

Poland, Canada, Brazil, Belgium, Japan, United States, Argentina, Australia, Austria, Chile, Colombia, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, Portugal, Russian Federation, Spain, Switzerland, Taiwan, Ukraine, United...
Cue Biopharma
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
University of Maryland, Baltimore

Active, not recruiting

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) (SAVER)

Head and Neck Cancer | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
Lawson Health Research Institute

Active, not recruiting

A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR) (ORATOR)

Early-Stage Squamous Cell Carcinoma of the Oropharynx

Canada, Australia
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Norway, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil
Vyriad, Inc.
Regeneron Pharmaceuticals

Recruiting

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Melanoma | Head and Neck Squamous Cell Carcinoma | Colo-rectal Cancer

United States, Brazil
Amgen

Completed

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

United States, Belgium, Czechia, Spain, Austria, France, Lithuania, Puerto Rico, Slovakia
Atreca, Inc.

Terminated

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Melanoma | Breast Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Acral Lentiginous Melanoma | Platinum-Resistant Fallopian... and other conditions

United States
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Canadian Cancer Trials Group

Active, not recruiting

De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma (EVADER)

Oropharyngeal Cancer

Canada
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Genmab

Completed

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Cancer

Sweden, United Kingdom, France, Hungary, Canada, Brazil, Belgium, Lithuania, Russian Federation, Serbia, Estonia, Poland
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Terminated

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

HIV Infection | Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
CEL-SCI Corporation
Teva Branded Pharmaceutical Products R&D, Inc.; Orient Europharma Co., Ltd.

Completed

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (IT-MATTERS)

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Soft Palate

Spain, Taiwan, United States, United Kingdom, Romania, India, Croatia, Belarus, Hungary, Bosnia and Herzegovina, Russian Federation, Austria, Canada, France, Israel, Italy, Malaysia, Poland, Serbia, Sri Lanka, Thailand, Turkey, Ukraine
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

Tongue Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell Carcinoma

United States, Canada, Saudi Arabia, Ireland
Genmab

Completed

Zalutumumab in Non-curable Patients With SCCHN

Head and Neck Cancer | Squamous Cell Cancer

United States, Germany, Israel, Colombia, Czechia, Austria, Chile, Italy, Peru, Portugal, Slovakia
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Stage... and other conditions

United States, Canada, Hong Kong

Clinical Trials on Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck in Colombia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations